2024-11-12 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on developing and commercializing therapies for serious and life-threatening diseases, primarily in cystic fibrosis.

**1. Performance vs. S&P 500 (VOO)**

| Year       | CAGR | MDD  | Alpha | Beta | Market Cap (B) | Cumulative Return |
|------------|------|------|-------|------|---------------|--------------------|
| 2015-2017  | 21.8% | 40.8% | -8.4% | 1.6 | 38.59 | NA                 |
| 2016-2018  | 34.8% | 35.1% | 10.2% | 1.5 | 42.68 | NA                 |
| 2017-2019  | 192.4% | 19.3% | 149.3% | 1.2 | 56.39 | NA                 |
| 2018-2020  | 54.6% | 30.3% | 15.5% | 0.9 | 60.86 | NA                 |
| 2019-2021  | 33.8% | 37.4% | -56.0% | 0.8 | 56.55 | NA                 |
| 2020-2022  | 31.6% | 37.4% | 13.9% | 0.7 | 74.37 | NA                 |
| 2021-2023  | 77.3% | 23.4% | 48.5% | 0.6 | 104.79 | NA                 |
| 2022-2024  | 132.2% | 17.2% | 107.0% | 0.6 | 129.40 | 197.69%          |
| **S&P 500** | **N/A** | **N/A** | **N/A** | **N/A** | **N/A** | **142.82%** |

**Analysis:** VRTX has outperformed the S&P 500 significantly, with a cumulative return of 197.69% compared to 142.82% for the S&P 500. This translates to a current outperformance of 54.87%, placing it in the 83.79% percentile compared to historical data. VRTX's Alpha consistently demonstrates its ability to outperform the market, showcasing its strong underlying fundamentals and growth potential.

**2. Recent Price Action**

* **Closing Price:** 516.74 (Last-market: 506.03)
* **5-Day Moving Average:** 497.1
* **20-Day Moving Average:** 483.26
* **60-Day Moving Average:** 476.94

**Analysis:** VRTX is currently trading above its 5-, 20-, and 60-day moving averages, indicating positive momentum and potential for further upside. The last-market price of 506.03 suggests a slight retracement from the closing price, but remains well above the moving averages.

**3. RSI, PPO, and Delta_Previous_Relative_Divergence**

* **RSI:** 71.09
* **PPO:** 0.79
* **Delta_Previous_Relative_Divergence:** 7.18 (+) - Short-term uptrend

**Analysis:** The RSI indicates that VRTX is in overbought territory, suggesting potential for a pullback. However, the PPO, which is above zero and positive, supports the short-term uptrend. The positive Delta_Previous_Relative_Divergence reinforces this short-term bullish outlook. 

**Expected Return:** 5.91% - This represents the estimated excess return over the S&P 500 for long-term (2+ years) investors.

**4. Recent Earnings and Outlook**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2024-11-05 | 4.05 | 2.77 B$     |
| 2024-08-02 | -13.92 | 2.65 B$     |
| 2024-05-07 | 4.26 | 2.69 B$     |
| 2023-11-07 | 4.01 | 2.48 B$     |
| 2024-11-05 | 4.01 | 2.48 B$     |

**Analysis:** The most recent earnings report (2024-11-05) showed an EPS of 4.05 and revenue of 2.77 B$, exceeding analysts' expectations. This positive result signifies strong performance and robust demand for Vertex's products.

**5. Financial Information**

**1) Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|-------------|----------|---------------|
| 2024-09-30  | $2.77B  | 85.84%        |
| 2024-06-30  | $2.65B  | 85.94%        |
| 2024-03-31  | $2.69B  | 87.27%        |
| 2023-12-31  | $2.52B  | 85.38%        |
| 2023-09-30  | $2.48B  | 87.17%        |

**2) Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|-------------|----------|-----------|
| 2024-09-30  | $15.63B | 6.69%     |
| 2024-06-30  | $14.77B | -24.32%   |
| 2024-03-31  | $18.55B | 5.93%     |
| 2023-12-31  | $17.58B | 5.51%     |
| 2023-09-30  | $16.51B | 6.27%     |

**Analysis:** Vertex consistently demonstrates strong revenue growth and high profitability. Its profit margin hovers around 85%, indicating efficient operations and a strong competitive advantage.  ROE has fluctuated in recent quarters, indicating potential volatility in profitability. 

**6. News and Recent Issues**

* **Recent Earnings Release:** Vertex exceeded analysts' expectations for the most recent quarter, with revenue exceeding 2.77B$ and EPS reaching 4.05. This positive result was driven by continued growth in its core cystic fibrosis treatments. 
* **Recent Market Outlook:** Analysts remain optimistic about Vertex's long-term growth prospects. Its strong pipeline of potential treatments and ongoing innovation within the cystic fibrosis market continue to attract investors.
* **Analyst Opinions and Performance Highlights:**  FINBOLD analysts continue to rate VRTX as a **"Buy"** with a target price of $550, indicating potential for further upside. The company's consistent financial performance and promising future prospects continue to attract investors.

**7.  Overall Analysis**

Vertex Pharmaceuticals (VRTX) is a strong investment option with a track record of exceeding expectations. Its dominant position in the cystic fibrosis market, robust financial performance, and promising pipeline of new treatments provide a compelling investment opportunity. While the stock is currently in overbought territory, its strong fundamentals and expected growth potential justify its current valuation. 

**8. Recommendation:**

VRTX is a strong investment for long-term investors with a high tolerance for risk. The company's commitment to innovation and its dominant market position indicate potential for continued growth and future value appreciation. However, investors should remain aware of the potential for volatility in the biotechnology sector and be prepared for potential short-term pullbacks. 
